Activist Investor Starboard Acquires Stake In Band-Aid Maker Kenvue, Shares Jump

person using MacBook Pro on table

Image Source: Unsplash
 

Hedge fund Starboard Value has reportedly taken a stake in Kenvue Inc. (NYSE: KVUE), the consumer products spinoff from Johnson & Johnson (NYSE: JNJ). The news, reported on October 20, 2024, by Reuters, comes as Kenvue’s stock has struggled since its public debut in May 2023, falling 18% and valuing the company at $41 billion.
 

Activist Investor Starboard Value Takes Stake in JNJ Consumer Products Spinoff Company

Starboard Value, known for its activist positions in companies, may push Kenvue to review its brand positioning and pricing strategies. The hedge fund’s chief investment officer, Jeffrey Smith, is scheduled to present investment ideas at the upcoming 13D Monitor Active-Passive Investor Summit. This move follows Starboard’s recent $1 billion investment in pharmaceutical giant Pfizer.

Kenvue, maker of household names such as Band-Aid, Listerine, and Tylenol, was spun off from Johnson & Johnson in May 2023. The company operates in the consumer products sector, focusing on personal care and over-the-counter medications.
 

Kenvue Stocks Jump on Activist Investor News

Following the news, Kenvue’s stock showed significant movement in pre-market trading. After closing at $21.72 on Friday, the stock jumped to $23.40 in pre-market activity, representing a 7.73% increase.

This surge brings Kenvue’s share price closer to analyst price targets, which range from $21.00 to $27.00.
For retail investors, Starboard’s involvement could signal potential changes in Kenvue’s business strategy aimed at improving performance and stock price.

However, it’s important to note that activist investors often push for significant operational changes, which could lead to short-term stock volatility. The long-term implications will depend on the specific actions Starboard proposes and their implementation.

Kenvue’s financial metrics reveal a mixed picture. With a market capitalization of $41.597 billion, the company trades at a price-to-earnings ratio of 38.11, with a forward P/E of 17.57.

Kenvue’s year-to-date return of 4.00% lags behind the S&P 500’s 22.95% gain, although its one-year return of 14.39% shows some promise.


More By This Author:

3 Small-Cap AI Stocks Worth Holding In October 2024
American Express Reports Third Quarter Results With $3.49 EPS, $16.6 B In Revenue
Procter & Gamble Reports Mixed First Quarter Results With $21.7 Billion In Net Sales

Disclaimer: The author does not hold or have a position in any securities discussed in the article.

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Or Sign in with